Geode Capital Management
CARM

Geode Capital Management’s Carisma Therapeutics CARM Stock Holding History

Geode Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250,495
Closed -$68.7K – 4489
2025
Q3 		$68.7K Hold
250,495
– – ﹤0.01% 4220
2025
Q2 		$98.1K Buy
250,495
+6,154
+3% +$1.65K ﹤0.01% 4066
2025
Q1 		$75.8K Sell
244,341
-14,843
-6% -$6.58K ﹤0.01% 4103
2024
Q4 		$109K Hold
259,184
– – ﹤0.01% 4074
2024
Q3 		$254K Sell
259,184
-24,224
-9% -$26.2K ﹤0.01% 3824
2024
Q2 		$431K Sell
283,408
-245,181
-46% -$366K ﹤0.01% 3621
2024
Q1 		$1.2M Buy
528,589
+12,696
+2% +$30.5K ﹤0.01% 3296
2023
Q4 		$1.51M Buy
515,893
+12,107
+2% +$36K ﹤0.01% 3193
2023
Q3 		$2.13M Sell
503,786
-36,210
-7% -$229K ﹤0.01% 3059
2023
Q2 		$4.74M Buy
539,996
+421,293
+355% +$2.29M ﹤0.01% 2713
2023
Q1 		$368K Buy
118,703
+3,956
+3% +$37.7K ﹤0.01% 3769
2022
Q4 		$1.4M Buy
114,747
+556
+0.5% +$5.84K ﹤0.01% 3206
2022
Q3 		$970K Sell
114,191
-2,291
-2% -$31.2K ﹤0.01% 3405
2022
Q2 		$1.89M Sell
116,482
-94,582
-45% -$1.08M ﹤0.01% 3132
2022
Q1 		$2.54M Sell
211,064
-14,524
-6% -$203K ﹤0.01% 3136
2021
Q4 		$3.68M Buy
225,588
+94,538
+72% +$1.9M ﹤0.01% 3064
2021
Q3 		$2.08M Sell
131,050
-11,478
-8% -$551K ﹤0.01% 3328
2021
Q2 		$13.2M Buy
142,528
+77,345
+119% +$4.93M ﹤0.01% 2269
2021
Q1 		$3.39M Buy
65,183
+24,126
+59% +$1.14M ﹤0.01% 2975
2020
Q4 		$1.11M Buy
41,057
+2,023
+5% +$51.3K ﹤0.01% 3340
2020
Q3 		$1.09M Buy
39,034
+1,243
+3% +$24.9K ﹤0.01% 3179
2020
Q2 		$544K Buy
37,791
+950
+3% +$12.8K ﹤0.01% 3342
2020
Q1 		$413K Buy
36,841
+685
+2% +$11.2K ﹤0.01% 3333
2019
Q4 		$752K Buy
36,156
+1,854
+5% +$42.6K ﹤0.01% 3369
2019
Q3 		$802K Buy
34,302
+8,698
+34% +$204K ﹤0.01% 3310
2019
Q2 		$768K Buy
25,604
+3,348
+15% +$100K ﹤0.01% 3313
2019
Q1 		$458K Hold
22,256
– – ﹤0.01% 3467
2018
Q4 		$632K Hold
22,256
– – ﹤0.01% 3280
2018
Q3 		$957K Buy
22,256
+2,176
+11% +$84.8K ﹤0.01% 3240
2018
Q2 		$783K Buy
20,080
+17,269
+614% +$761K ﹤0.01% 3281
2018
Q1 		$59K Hold
2,811
– – ﹤0.01% 3929
2017
Q4 		$45K Hold
2,811
– – ﹤0.01% 3932
2017
Q3 		$88K Hold
2,811
– – ﹤0.01% 3845
2017
Q2 		$88K Buy
2,811
+452
+19% +$15.1K ﹤0.01% 3866
2017
Q1 		$103K Buy
2,359
+15
+0.6% +$625 ﹤0.01% 3824
2016
Q4 		$89K Buy
2,344
+10
+0.4% +$441 ﹤0.01% 3808
2016
Q3 		$130K Buy
2,334
+2
+0.1% +$149 ﹤0.01% 3734
2016
Q2 		$77K Hold
2,332
– – ﹤0.01% 3855
2016
Q1 		$14 Sell
2,332
-2
-0.1% -$28 ﹤0.01% 4074
2015
Q4 		$140K Buy
2,334
+5
+0.2% +$284 ﹤0.01% 3792
2015
Q3 		$112K Buy
2,329
+5
+0.2% +$308 ﹤0.01% 3868
2015
Q2 		$131K Buy
2,324
+368
+19% +$51.9K ﹤0.01% 3705
2015
Q1 		$348K Buy
1,956
+408
+26% +$89.1K ﹤0.01% 3350
2014
Q4 		$367K Buy
1,548
+7
+0.5% +$1.57K ﹤0.01% 3327
2014
Q3 		$343K Buy
1,541
+351
+29% +$83.4K ﹤0.01% 3336
2014
Q2 		$313K Buy
1,190
+109
+10% +$27K ﹤0.01% 3364
2014
Q1 		$350K Buy
+1,081
New +$324K ﹤0.01% 3299

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Geode Capital Management's CARM Position: Q4 2025 in Review

Geode Capital Management sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 250,495 shares — an estimated $68.7K sold.

Geode Capital Management first reported a position in CARM in Q1 2014 and held it in 47 quarters. The position peaked at $13.2M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Geode Capital Management reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Geode Capital Management sold 250,495 Carisma Therapeutics shares in Q4 2025, an estimated $68.7K.
  • Geode Capital Management first reported a position in Carisma Therapeutics in Q1 2014 and held it in 47 quarters.
  • Geode Capital Management's Carisma Therapeutics position peaked at $13.2M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.